静脉注射67镓在非霍奇金淋巴瘤中的治疗潜力。

Therapeutic potential of intravenous 67-gallium in non-Hodgkin's lymphoma.

作者信息

Huijgens P C, Jonkhoff A R, Hoekstra O S, Ossenkoppele G J, Teule G J

机构信息

Department of Haematology, Free University Hospital, Amsterdam, The Netherlands.

出版信息

Eur J Haematol. 1993 Oct;51(4):206-8. doi: 10.1111/j.1600-0609.1993.tb00631.x.

DOI:10.1111/j.1600-0609.1993.tb00631.x

PMID:8243608

Abstract

67-gallium accumulates rather selectively in malignant lymphoid tissue. The isotope has a substantial cytotoxic effect in human-derived cell-lines. 67-gallium was given intravenously to 3 patients with end-stage, resistant large-cell lymphoma. Evaluation of tumour response was done by physical measurements, and CT-scanning together with gallium scintigraphy. Three weekly doses of 20, 40 and 60 mCi respectively caused persistent pancytopenia in 1 patient. Pancytopenia was not observed in 2 other patients given two 40 mCi doses 4 weeks apart. In all 3 patients, some response was noted, be it shortlived and different from site to site. 67-gallium has some cytostatic effect in large cell lymphoma. It seems feasible to start a phase I study to find a tolerable dose to be given every 4 weeks.

摘要

67镓相当有选择性地在恶性淋巴组织中蓄积。该同位素对源自人类的细胞系有显著的细胞毒性作用。对3例终末期、耐药性大细胞淋巴瘤患者静脉注射67镓。通过体格检查、CT扫描以及镓闪烁扫描对肿瘤反应进行评估。分别给予3周剂量的20、40和60毫居里，导致1例患者出现持续性全血细胞减少。另外2例相隔4周给予两剂40毫居里的患者未观察到全血细胞减少。在所有3例患者中，均观察到了一些反应，尽管反应短暂且部位各异。67镓在大细胞淋巴瘤中有一定的细胞生长抑制作用。启动一项I期研究以找到每4周可耐受的给药剂量似乎是可行的。